Brandy Was a Hit Drink. Now It's a Poster Child for the Trade Wars. The preferred quaff of aristocrats and rappers is a key export for European luxury-drink makers, which are fighting tariff assaults ...

Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to treatment is often subject to extended insurance authorization delays, ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.

Lilly’s FRα targeting ADC is composed of an Fc-silent, FRα specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker.

Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety ...

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156 ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. From tariffs to inflation ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.